VKTX

Viking Therapeutics, Inc.

September 22, 2026 · pre-market

Rarity

6.63

Peak move

+48.75%

Float cap

$3.4B

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on novel therapies for metabolic and endocrine disorders. It is developing VK2735 for patients with obesity and related metabolic conditions, VK2809 for NASH/MASH, and VK0214 for X-linked adrenoleukodystrophy, while also advancing a preclinical dual amylin and calcitonin receptor agonist program for obesity.

• Timed with the moveclinical_readoutSep 22 · 07:05 ET

  Viking Therapeutics reported topline results from its maintenance dosing study of GLP-1/GIP agonist VK2735, showing 22% placebo-adjusted weight loss at Week 33 with weekly 17.5 mg dosing, no plateau, weight loss maintained with every-other-week and monthly regimens, and up to 97% of weight loss maintained on every-other-week dosing.

  SEC8-K 0001193125-26-397219wireprnewswire.comWebarchive.fast-edgar.comWebinvestors.comWebir.vikingtherapeutics.comWebmarketscreener.comWebus.kabutan.jpWebgurufocus.com
• analyst_ratingSep 21

  Oppenheimer reiterated an Outperform rating and $100 price target on Viking Therapeutics, saying upcoming VK2735 maintenance data could refute the bear thesis that Eli Lilly's tirzepatide will dominate the GLP-1/GIP class.

  Webfr.investing.comWebes.investing.com